121 related articles for article (PubMed ID: 20949910)
1. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S
Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.
Gilad Y; Noy E; Senderowitz H; Albeck A; Firer MA; Gellerman G
Bioorg Med Chem; 2016 Jan; 24(2):294-303. PubMed ID: 26719208
[TBL] [Abstract][Full Text] [Related]
4. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
5. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
[TBL] [Abstract][Full Text] [Related]
6. Antitumor agents 216. Synthesis and evaluation of paclitaxel-camptothecin conjugates as novel cytotoxic agents.
Ohtsu H; Nakanishi Y; Bastow KF; Lee FY; Lee KH
Bioorg Med Chem; 2003 Apr; 11(8):1851-7. PubMed ID: 12659771
[TBL] [Abstract][Full Text] [Related]
7. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents.
Zhu L; Zhuang C; Lei N; Guo Z; Sheng C; Dong G; Wang S; Zhang Y; Yao J; Miao Z; Zhang W
Eur J Med Chem; 2012 Oct; 56():1-9. PubMed ID: 23084702
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
[TBL] [Abstract][Full Text] [Related]
10. Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.
Dal Pozzo A; Ni MH; Esposito E; Dallavalle S; Musso L; Bargiotti A; Pisano C; Vesci L; Bucci F; Castorina M; Foderà R; Giannini G; Aulicino C; Penco S
Bioorg Med Chem; 2010 Jan; 18(1):64-72. PubMed ID: 19942441
[TBL] [Abstract][Full Text] [Related]
11. Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Beretta GL; Zuco V; De Cesare M; Perego P; Zaffaroni N
Curr Med Chem; 2012; 19(21):3488-501. PubMed ID: 22680917
[TBL] [Abstract][Full Text] [Related]
12. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Nakada T; Masuda T; Naito H; Yoshida M; Ashida S; Morita K; Miyazaki H; Kasuya Y; Ogitani Y; Yamaguchi J; Abe Y; Honda T
Bioorg Med Chem Lett; 2016 Mar; 26(6):1542-1545. PubMed ID: 26898815
[TBL] [Abstract][Full Text] [Related]
13. β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate.
López Rivas P; Müller C; Breunig C; Hechler T; Pahl A; Arosio D; Belvisi L; Pignataro L; Dal Corso A; Gennari C
Org Biomol Chem; 2019 May; 17(19):4705-4710. PubMed ID: 31020985
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel dual-cyclic RGD peptides for α
Liu J; Cheng X; Tian X; Guan D; Ao J; Wu Z; Huang W; Le Z
Bioorg Med Chem Lett; 2019 Apr; 29(7):896-900. PubMed ID: 30732943
[TBL] [Abstract][Full Text] [Related]
15. Novel 99mTc '4 + 1' peptide conjugates: tuning the biodistribution by variation of coligands.
Kunstler JU; Seidel G; Bergmann R; Gniazdowska E; Walther M; Schiller E; Decristoforo C; Stephan H; Haubner R; Steinbach J; Pietzsch HJ
Eur J Med Chem; 2010 Sep; 45(9):3645-55. PubMed ID: 20570022
[TBL] [Abstract][Full Text] [Related]
16. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
17. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Redko B; Tuchinsky H; Segal T; Tobi D; Luboshits G; Ashur-Fabian O; Pinhasov A; Gerlitz G; Gellerman G
Oncotarget; 2017 Jan; 8(1):757-768. PubMed ID: 27768593
[TBL] [Abstract][Full Text] [Related]
18. Polymeric phosphorylcholine-camptothecin conjugates prepared by controlled free radical polymerization and click chemistry.
Chen X; McRae S; Parelkar S; Emrick T
Bioconjug Chem; 2009 Dec; 20(12):2331-41. PubMed ID: 19899739
[TBL] [Abstract][Full Text] [Related]
19. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents.
Lerchen HG; Baumgarten J; von dem Bruch K; Lehmann TE; Sperzel M; Kempka G; Fiebig HH
J Med Chem; 2001 Nov; 44(24):4186-95. PubMed ID: 11708920
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues.
Sugimori M; Ejima A; Ohsuki S; Uoto K; Mitsui I; Kawato Y; Hirota Y; Sato K; Terasawa H
J Med Chem; 1998 Jun; 41(13):2308-18. PubMed ID: 9632364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
